Unknown PHASE1 INTERVENTIONAL 1-arm NCT04056975

Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma (A-319)

A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

Sponsor: EVIVE Biotechnology

Conditions Relapsed or Refractory B-cell Lymphoma

Interventions Recombinant Anti-CD19m-CD3 Antibody Injection

Updated 7 times since 2019 Last updated: Aug 13, 2019 Started: Sep 15, 2019 Primary completion: Sep 30, 2021 Completion: Jan 27, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Relapsed or Refractory B-cell Lymphoma and is currently ongoing. EVIVE Biotechnology leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE1
Mar 2022 — Nov 2022 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2022 — Mar 2022 [monthly]

Not Yet Recruiting PHASE1

▶ Show 2 earlier versions

Jan 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE1
Sep 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EVIVE Biotechnology
Peking University Cancer Hospital & Institute

Data source: EVIVE Biotechnology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.